Ipilimumab vs Lutetium Oxodotreotide Lu-177
Ipilimumab vs Lutetium Oxodotreotide Lu-177: Overview
This comparison examines the pharmacological differences between Ipilimumab and Lutetium Oxodotreotide Lu-177.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days.
Chemical Properties
Type: Ipilimumab — Antibody; Lutetium Oxodotreotide Lu-177 — Protein.